Table 2 Baseline characteristics of MN patients with or without malignant tumors
Malignant tumor group (n = 174) | Control group (n = 604) | P value | |
|---|---|---|---|
Male (%) | 89 (51.1) | 346 (57.4) | 0.145 |
Age (years) | 58 (47, 66) | 48 (37, 58) | < 0.001 |
PLA2R Ab (U/mL) | 15.10 (2.10, 83.65) | 29.5 (9.33, 84.58) | 0.001 |
PLA2R Ab (+) | 76 (51.0) | 338 (66.1) | 0.001 |
THSD7A Ab (ng/mL) | 58.10 (24.40, 162.90) | 59.80 (38.30, 97.20) | 0.885 |
Hb (g/L) | 123.00 (108.00, 136.00) | 131.00 (121.00, 142.85) | < 0.001 |
GLU (mmol/L) | 4.85 (4.41, 5.33) | 4.47 (4.10, 4.99) | < 0.001 |
ALB (g/L) | 27.00 (22.20, 31.88) | 26.10 (22.20, 31.20) | 0.258 |
ESR (mm/h) | 49.00 (19.25, 75.00) | 26.00 (14.00, 43.00) | < 0.001 |
CRP (mg/L) | 1.39 (0.50, 3.38) | 0.90 (0.10, 1.90) | < 0.001 |
sCr (umol/L) | 65.50 (53.00, 87.00) | 65.00 (55.00, 76.00) | 0.064 |
UA (umol/L) | 304.00 ( 252.00, 372.75) | 310.00( 258.00, 373.00) | 0.634 |
24hUTP (g) | 4.90 (2.64, 8.10) | 3.86 (2.10, 6.23) | 0.003 |
Pathological stage: | < 0.001 | ||
1 | 11 (7.4) | 95 (15.7) | |
2 | 95 (63.8) | 398 (65.9) | |
3 | 39 (26.2) | 111 (18.4) | |
4 | 4 (2.7) | 0 (0) | |
Tubular atrophy: | < 0.001 | ||
0 | 61 (37.7) | 348 (57.6) | |
1 | 39 (24.1) | 61 (10.1) | |
2 | 35 (21.6) | 100 (16.6) | |
3 | 27 (16.7) | 95 (15.7) | |
Interstitial fibrosis: | 0.008 | ||
0 | 80 (49.4) | 333 (55.1) | |
1 | 42 (25.9) | 101 (16.7) | |
2 | 33 (20.4) | 159 (26.3) | |
3 | 7 (4.3) | 11 (1.8) | |
Renal arteriole injury: | < 0.001 | ||
0 | 26 (16.0) | 270 (44.7) | |
1 | 31 (19.1) | 162 (26.8) | |
2 | 105 (64.8) | 172 (28.5) | |
IgG | < 0.001 | ||
0 | 5 (3.1) | 14 (2.3) | |
1 | 4 (2.5) | 58 (9.6) | |
2 | 73 (45.1) | 391 (64.7) | |
3 | 75 (46.3) | 141 (23.3) | |
4 | 5 (3.1) | 0 (0) | |
IgM | < 0.001 | ||
0 | 43 (28.7) | 389 (64.4) | |
1 | 52 (34.7) | 151 (25.0) | |
2 | 54 (36.0) | 64 (10.6) | |
3 | 1 (0.7) | 0 (0) | |
IgA | < 0.001 | ||
0 | 119 (73.5) | 591 (97.8) | |
1 | 26 (16.0) | 7 (1.2) | |
2 | 17 (10.5) | 6 (1.0) | |
C3 | < 0.001 | ||
0 | 49 (30.2) | 267 (44.2) | |
1 | 32 (19.8) | 183 (30.3) | |
2 | 73 (45.1) | 149 (24.7) | |
3 | 8 (4.9) | 5 (0.8) | |
C4 | < 0.001 | ||
0 | 87 (59.2) | 518 (85.8) | |
1 | 40 (27.2) | 69 (11.4) | |
2 | 20 (13.6) | 17 (2.8) | |
C1q | < 0.001 | ||
0 | 120 (74.5) | 579 (95.9) | |
1 | 28 (17.4) | 23 (3.8) | |
2 | 13 (8.1) | 2 (0.3) | |
IgG1 | < 0.001 | ||
0 | 42 (29.0) | 345 (57.1) | |
1 | 46 (31.7) | 152 (25.2) | |
2 | 51 (35.2) | 104 (17.2) | |
3 | 6 (4.1) | 3 (0.5) | |
IgG2 | < 0.001 | ||
0 | 84 (58.3) | 575 (95.2) | |
1 | 40 (27.8) | 26 (4.3) | |
2 | 20 (13.9) | 3 (0.5) | |
IgG3 | < 0.001 | ||
0 | 105 (72.4) | 547 (90.6) | |
1 | 21 (14.5) | 35 (5.8) | |
2 | 19 (13.1) | 22 (3.6) | |
IgG4 | < 0.001 | ||
0 | 30 (20.5) | 0 (0) | |
1 | 11 (7.5) | 73 (12.1) | |
2 | 71 (48.6) | 395 (65.4) | |
3 | 34 (23.3) | 136 (22.5) | |
PLA2R | < 0.001 | ||
0 | 35 (28.2) | 215 (50.4) | |
1 | 15 (12.1) | 114 (26.7) | |
2 | 74 (59.7) | 98 (23.0) |